Humana (HUM) EBITDA (2009 - 2026)

Humana (HUM) has reported EBITDA for 18 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 19.01% year-over-year to $1.5 billion in Q2 2026; TTM through Jun 2026 was $3.4 billion, a 16.9% decrease from a year earlier, with the FY2025 full-year figure at $3.5 billion, changed 0.2% from the prior year.
• EBITDA was $1.5 billion for Q2 2026 at Humana, down from $1.9 billion in the prior quarter.
• Over five years, EBITDA peaked at $2.2 billion in Q1 2025 and troughed at -$622.0 million in Q4 2025.
• A 5-year average of $1.1 billion and a median of $1.4 billion in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA jumped 72.34% in 2022 and plunged 151.59% in 2024, its largest moves.
• Over 5 years, EBITDA stood at $318.0 million in 2022, then tumbled by 139.62% to -$126.0 million in 2023, then sank by 151.59% to -$317.0 million in 2024, then tumbled by 96.21% to -$622.0 million in 2025, then surged by 347.59% to $1.5 billion in 2026.
• The last three EBITDA figures came in at $1.5 billion (Q2 2026), $1.9 billion (Q1 2026), and -$622.0 million (Q4 2025), per Business Quant data.